SCHEMBL3484059

SCHEMBL3484059

COc1cccc(Sc2ccc(C)cc2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.53
MTNR1A P48039 1/20 0.52
MTNR1B P49286 1/20 0.52
PTGIR P43119 1/20 0.50
MAOB P27338 1/20 0.49
SIRT2 Q8IXJ6 1/20 0.48
HTR2C P28335 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
HPGD P15428 1/20 0.45
THRB P10828 1/20 0.45
DHFR P00374 2/20 0.43
ABCG2 Q9UNQ0 1/20 0.43
IDO1 P14902 1/20 0.43
EDNRA P25101 1/20 0.43
HTR6 P50406 1/20 0.43
LRRK2 Q5S007 1/20 0.43
KDM4E B2RXH2 1/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
TSHR P16473 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31345530 1.00 ACHE (0.53) ACHEMTNR1AMTNR1BPTGIRMAOB
SCHEMBL10709610 0.92 MTNR1A (0.57) ACHEMTNR1AMTNR1BPTGIRSIRT2
SCHEMBL9770219 0.89 HTR2C (0.55) ACHEMTNR1AMTNR1BPTGIRSIRT2
SCHEMBL31425668 0.88 ACHE (0.54) ACHEMTNR1AMTNR1BPTGIRDHFR
SCHEMBL3164341 0.88 ACHE (0.54) ACHEMTNR1AMTNR1BPTGIRDHFR
SCHEMBL13163776 0.86 EDNRA (0.54) ACHEMTNR1AMTNR1BPTGIRMAOB
SCHEMBL24433577 0.86 ACHE (0.52) ACHEMTNR1AMTNR1BPTGIRHTR2C
SCHEMBL4806373 0.84 IDO1 (0.56) ACHEMTNR1AMTNR1BPTGIRSIRT2
SCHEMBL8569510 0.83 DHFR (0.44) ACHEMTNR1AMTNR1BPTGIRMAOB
SCHEMBL31351860 0.82 ACHE (0.50) ACHEPTGIRHTR2CSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES GENFIT (FR) 2010-01-07 US disclosed
EP-2049107-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES Genfit (FR) 2009-04-22 EP disclosed
WO-2008012470-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES GENFIT (FR) 2008-01-31 WO disclosed
WO-2008012470-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES GENFIT (FR) 2008-01-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004159-A1 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES IPO5, PPIP5K2, IPO4 ACHE 2077/4885MTNR1A 2930/4885MTNR1B 1868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.